Ubs Asset Management Americas Inc Verve Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 119,818 shares of VERV stock, worth $692,548. This represents 0.0% of its overall portfolio holdings.
Number of Shares
119,818
Previous 115,041
4.15%
Holding current value
$692,548
Previous $556,000
21.4%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding VERV
# of Institutions
179Shares Held
76.1MCall Options Held
70.3KPut Options Held
194K-
Alphabet Inc. Mountain View, CA12.3MShares$71.4 Million4.92% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$39.9 Million1.46% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$38.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$23.2 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$23.1 Million1.94% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $346M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...